Monitor for upcoming Phase II data readouts in Q4 2026, which could be pivotal for the drug's development. The durable effects after short-term treatment suggest a potentially transformative mechanism, making this a high-risk, high-reward catalyst for the stock.
Price Chart
Executive Summary
Biomea Fusion updated its corporate presentation, highlighting positive clinical data from its Phase II trial (COVALENT-111) for icovamenib in type 2 diabetes. The data shows durable HbA1c reduction and increased C-peptide levels lasting 52 weeks after a 12-week treatment course, suggesting potential disease modification. The company is advancing two Phase II trials with data expected in Q4 2026 and is funded into Q1 2027.
Key Facts
- Icovamenib demonstrated durable HbA1c reduction of 1.2% at 52 weeks after a 12-week treatment course in insulin-deficient T2D patients (p=0.01).
- Icovamenib increased insulin secretion (C-peptide) by 24% at 52 weeks in severe insulin-deficient patients.
- Two Phase II trials (COVALENT-211 and COVALENT-212) are ongoing with 26-week primary endpoint data anticipated in Q4 2026.
- The drug showed a favorable 52-week safety profile with no treatment-related serious adverse events.
- Biomea is funded through key clinical readouts for icovamenib and BMF-650 into Q1 2027.
Financial Impact
No direct financial figures provided in the filing.
Risk Factors
- Clinical trial results may not be replicated in larger studies.
- Regulatory approval is not guaranteed despite positive early data.
- Competition from existing and emerging diabetes treatments.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-068375 |
| Document: d95198d8k.htm | 0001193125-26-068375 |
| Document: 0001193125-26-068375-index-headers.html | 0001193125-26-068375 |
| Document: 0001193125-26-068375-index.html | 0001193125-26-068375 |
| Document: 0001193125-26-068375.txt | 0001193125-26-068375 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 8-K | $0.8340 $0.6901 | ▼ −17.25% | ▼ −17.71% | $0.6155 (−26.20%) |
Oct 13, 2026 13d ago | Press Release | $0.8340 $0.6901 | ▼ −17.25% | ▼ −17.71% | $0.6155 (−26.20%) |
Sep 23, 2026 4w ago | Press Release | $1.44 $1.33 | ▼ −7.64% | ▼ −6.96% | $0.6155 (−57.26%) |
Sep 22, 2026 4w ago | 424B5 | $1.44 $1.33 | ▲ +7.64% | ▲ +6.96% | $0.6155 (+57.26%) |
Sep 22, 2026 4w ago | Press Release | $1.44 $1.33 | ▲ +7.64% | ▲ +6.96% | $0.6155 (+57.26%) |
Jun 12, 2026 19w ago | Institutional Cluster | $1.17 $1.18 | ▲ +0.85% | ▲ +0.18% | $0.6155 (−47.39%) |
Jun 5, 2026 20w ago | Press Release | $1.15 $1.20 | ▲ +4.35% | ▲ +2.24% | $0.6155 (−46.48%) |
May 11, 2026 24w ago | 8-K | $1.58 $1.25 | ▼ −20.89% | ▼ −20.96% | $0.6155 (−61.04%) |
May 11, 2026 24w ago | Press Release | $1.58 $1.25 | ▼ −20.89% | ▼ −20.96% | $0.6155 (−61.04%) |
Apr 28, 2026 26w ago | 8-K | $1.53 $1.48 | ▼ −3.27% | ▼ −4.96% | $0.6155 (−59.77%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers